Clipos™ FLT3L mRNA Lipid Nanoparticles

Catalog:CDL23-057-L

Unit Size:200 μL

INQUIRY Datasheet

Specifications
Description FLT3LG (fms-associated receptor tyrosine kinase 3 ligand, FLT3L for short) is a hematopoietic cytokine encoded by the FLT3LG gene, which binds to and activates the receptor FLT3 on multipotent and common lymphoid progenitor cells to play a role. As a cytokine and growth factor, FLT3LG increases the number of immune cells (lymphocytes: B cells and T cells) by activating hematopoietic progenitor cells. FLT3LG is mainly produced by lymphocytes, especially T cells, while FLT3 is mainly expressed physiologically in DCs and pathologically expressed in malignant cells and progenitor cells. In fact, FLT3LG has been shown to bind to FLT3 on DCs, stimulating their differentiation and expansion, promoting tumor antigen cross-presentation and anticancer immune responses. However, in malignant conditions, FLT3 mutations induce receptor dimerization, leading to constitutive activation of PI3K-AKT, RAS-MEK-MAPK, and STAT-5 signaling pathways. The FLT3LG-FLT3 axis is a key pathway that promotes DC-based cross-priming of anti-leukemic T cells. This product is designed as a tool for the delivery and expression of FLT3 Ligand mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of FLT3 Ligand mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. FLT3LG protein is about 26 kD, consisting of 235 amino acids
Lipid composition SM-102/DSPC/Cholesterol/DMG-PEG2000
Encoding mRNA FLT3LG
In Vitro QC (Cell Types) HEK293S
Technology Applications Protein research
Storage Store at 4°C
Technical Notes Work with mRNA-LNP on ice. It is important to minimize the time that the product spends at room temperature; after handling product during experiments, return immediately to ice.Upon receiving product, briefly pulse spin before opening to ensure product is at bottom of container; it is important not to spin for too long as this may rupture mRNA-LNP’s. Do not vortex. mRNA-LNP products should only be handled with certified RNAase-free reagents and consumables; use of filtered pipette tips is highly recommended
Related Products
Product Name Catalog Lipid composition Liposome Size Price
Clipos™ EGFP mRNA Lipid Nanoparticles CDPM01 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ mCherry mRNA Lipid Nanoparticles CDPM02 INQUIRY
Clipos™ mCherry-Luciferase mRNA Lipid Nanoparticles CDPM03 INQUIRY
Clipos™ Luciferase mRNA Lipid Nanoparticles CDPM04 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ CAS 9-RNA Lipid Nanoparticles-HA CDPM05 INQUIRY
Clipos™ ANTI-BCMA mRNA Lipid Nanoparticles CDPM06 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ ANTI-CD19 mRNA Lipid Nanoparticles CDPM07 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ ANTI-HER2 mRNA Lipid Nanoparticles CDPM08 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Products
Fill out the form below
to receive a quote

GET A QUOTE

Services

Drug Targeting Strategy

Drug Delivery Nanoparticles Formulation

Bioparticles Analysis and Characterization

Bioactive Particles & Fillers Production

Functional Biomedical Coatings

Lipid Library Development for Drug Delivery

Aptamer Targeted Drug Delivery System

Other Types of Drug Delivery

Products

Liposome System

Chelating Agents

Bioactive Matrixes

Porous Organic Materials

Biopolymers & Synthetic Polymers

PROTAC

Transfection

Exosome Products

Cleavable Linkers

Pharmaceutical Excipients (drug/medical grade)

Tissue Engineering Scaffold

  • (USA)
  • (Europe)
Cookie Policy | Privacy Policy | Copyright © 2024 CD Bioparticles. All rights reserved.
0
Inquiry Basket
Inquiry